Once in the tumor, therapeutic agents that modulate the tumor microenvironment such as anti-PD1, anti-PD-L1, anti-TGFβ, anti-TIM-3, and others could be viable options (77, 79, 80). This evidence concerns the gene CD274 and neoplasm.